U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06917885) titled 'CUE-102 in Recurrent Glioblastoma' on April 07.
Brief Summary: The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM).
The name of the study drug involved in this study is:
-CUE-102 (a type of fusion protein)
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Recurrent Glioblastoma
Glioblastoma
Glioma, Malignant
Intervention:
BIOLOGICAL: CUE-102
A WT-1-pHLA-IL2-Fc fusion protein, single-use vial, via intravenous (into the vein) infusion per protocol.
Recruitment Status: NOT_YET_REC...